NCT00570284 - A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Cancer

Interventions

DRUG

LBH589

orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)

Trial Locations (9)

Unknown

Novartis Investigative Site, Los Angeles

Novartis Investigative Site, Norwalk

Novartis Investigative Site, Rockville

Novartis Investigative Site, Boston

Novartis Investigative Site, Lebanon

Novartis Investigative Site, New York

Novartis Investigative Site, Madison

Novartis Investigative Site, Stockholm

Novartis Investigative Site, Zurich